ATE312587T1 - Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen - Google Patents

Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen

Info

Publication number
ATE312587T1
ATE312587T1 AT01924517T AT01924517T ATE312587T1 AT E312587 T1 ATE312587 T1 AT E312587T1 AT 01924517 T AT01924517 T AT 01924517T AT 01924517 T AT01924517 T AT 01924517T AT E312587 T1 ATE312587 T1 AT E312587T1
Authority
AT
Austria
Prior art keywords
compositions
hair loss
prostaglandins
methods
treating hair
Prior art date
Application number
AT01924517T
Other languages
English (en)
Inventor
Mitchell Anthony Delong
John Mcmillan Mciver
Robert Scott Youngquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE312587T1 publication Critical patent/ATE312587T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01924517T 2000-03-31 2001-03-30 Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen ATE312587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19384600P 2000-03-31 2000-03-31
PCT/US2001/010368 WO2001074313A2 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins

Publications (1)

Publication Number Publication Date
ATE312587T1 true ATE312587T1 (de) 2005-12-15

Family

ID=22715257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01924517T ATE312587T1 (de) 2000-03-31 2001-03-30 Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen

Country Status (10)

Country Link
US (3) US20020037914A1 (de)
EP (1) EP1267803B1 (de)
JP (2) JP2003528897A (de)
CN (1) CN1206976C (de)
AT (1) ATE312587T1 (de)
AU (1) AU2001251166A1 (de)
CA (1) CA2401718C (de)
DE (1) DE60115869T2 (de)
ES (1) ES2254395T3 (de)
WO (1) WO2001074313A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
MXPA03009995A (es) 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
JP4891207B2 (ja) * 2007-11-27 2012-03-07 大洋香料株式会社 抗菌剤及びそれを含有する皮膚外用剤
US8455547B2 (en) 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3871671A3 (de) 2009-07-29 2022-03-09 Olsen, Elise Fp rezeptorantagonisten zur hemmung von haarwachstum
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
US20150190383A1 (en) * 2014-01-08 2015-07-09 Aida Kalley Hair care composition with analgesic
US11185487B2 (en) 2015-12-28 2021-11-30 Johnson & Johnson Consumer Inc. Hair growth composition and method
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
US12661364B2 (en) * 2019-06-28 2026-06-23 Koff Investments Llp Remedy for hair growth enhancing
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta

Family Cites Families (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13294A (en) 1855-07-17 Improved apparatus for cooling repeating fire-arms
US37914A (en) 1863-03-17 Improved automatic nose-bag
US146439A (en) 1874-01-13 Improvement in pruning-shears
US37913A (en) 1863-03-17 Improvement in sewing-machines
DE1617477U (de) 1950-09-27 1950-12-14 Heinrich Dressel Radhalter fuer raeder, beispielsweise fuer kinderwagen und kleinfahrzeuge.
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3839409A (en) * 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3776939A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
DE1801750U (de) 1959-07-07 1959-12-10 H L Wahrendorf Betonwerk Trog zur aufnahme des weichengestaenges von eisenbahngleisen.
US3382248A (en) * 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3524867A (en) * 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3538120A (en) 1967-05-22 1970-11-03 Ciba Geigy Corp Cyclopentyl-alkanoic acids
US3636120A (en) 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
GB1285372A (en) 1968-08-29 1972-08-16 Upjohn Co Improvements in or relating to prostaglandins and the preparation thereof
GB1251750A (de) 1968-11-12 1971-10-27
DE1910561A1 (de) 1969-03-01 1970-09-10 Herten Dr Med Kurt Mittel zur Verhuetung von Haarausfall
BE755555A (fr) * 1969-09-02 1971-03-01 Richardson Merrell Inc Derives de quinoxaline
US3882241A (en) * 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3896156A (en) * 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
IT1012505B (it) 1970-09-28 1977-03-10 Imes C Spa Estratto di ricci di mare
BE791369A (fr) 1971-11-16 1973-05-14 American Cyanamid Co Cyanurates de tris-(meta-hydroxybenzyle) faisant l'objet d'un empechement sterique et utilisables comme anti-oxydants
US3798275A (en) 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US3974213A (en) 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
US3984424A (en) 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4152527A (en) 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
IL43571A (en) 1972-11-08 1977-08-31 Pfizer Omega-pentanorprostaglandins and their preparation
DD118856A5 (de) 1972-11-08 1976-03-20
JPS49101356U (de) 1972-12-20 1974-08-31
JPS5320995Y2 (de) 1972-12-23 1978-06-02
JPS5720305B2 (de) * 1973-02-28 1982-04-27
US3984455A (en) * 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US4069885A (en) * 1974-03-27 1978-01-24 Klockner-Humboldt-Deutz Aktiengesellschaft Tractor-implement arrangement for establishing frictional engagement therebetween
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
GB1458315A (en) 1974-04-22 1976-12-15 Ici Ltd Prostanoic acid derivatives
DE2460990A1 (de) 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
GB1506817A (en) 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
GB1520522A (en) 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
ES449162A1 (es) 1975-06-23 1977-12-16 Syntex Inc Un procedimiento para la preparacion de un compuesto racemi-co u 8r-antimerico.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4051238A (en) 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
DE2635985A1 (de) * 1976-08-06 1978-02-09 Schering Ag Prostansaeurederivat und verfahren zu ihrer herstellung
DE2737808A1 (de) 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
DE2737807A1 (de) 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4123441A (en) * 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4206151A (en) 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
GB2048254B (en) 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
US4225508A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4225507A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4296504A (en) 1980-07-07 1981-10-27 Lawson Daniel C Toilet seat lock
JPH0222226Y2 (de) 1981-02-04 1990-06-14
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
CH656877A5 (de) 1981-11-27 1986-07-31 Erba Farmitalia Optisch aktive oder racemische prostaglandinderivate.
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
EP0187854A4 (de) 1984-07-13 1987-01-22 Gail S Bazzano Substituierte pyrimidinoxide, einsetzbar zur haarwachsanregung.
ZA855740B (en) 1984-07-31 1987-03-25 Syntex Inc 11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives
JPS61126069A (ja) * 1984-11-21 1986-06-13 Res Dev Corp Of Japan プロスタグランジン誘導体
JPS61218510A (ja) * 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd 毛髪用剤
US5863948A (en) 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
FI872552A7 (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Paikallisesti käytettävä prostaglandiinikoostumus.
US5041439A (en) 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
GB8713747D0 (en) 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
DE68929435T2 (de) 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
JPH0737389B2 (ja) 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
CA1339132C (en) 1989-09-12 1997-07-29 Johan W. Stjernschantz Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0627942Y2 (ja) 1989-12-14 1994-07-27 松下電器産業株式会社 ヒューズホルダー付コンデンサー
WO1991013207A1 (en) 1990-02-21 1991-09-05 Pulp And Paper Research Institute Of Canada POLY-β-HYDROXYALKANOATES FOR USE IN FIBRE CONSTRUCTS AND FILMS
TW249226B (de) 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5063057A (en) * 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
DE4024347A1 (de) 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
JPH04300833A (ja) 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
US5378840A (en) * 1992-04-16 1995-01-03 G. D. Searle & Co. Substituted dibenzoxazepine compounds
US5312832A (en) 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
US5817694A (en) * 1992-06-08 1998-10-06 New Pharma International Corp. 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
ES2105333T3 (es) 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5332730A (en) 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
DE4238830A1 (de) * 1992-11-17 1994-05-19 Anton Felder Verfahren zum hydraulischen Verzweigen einer offenen Strömung sowie hydraulisch arbeitende Kanalverzweigung
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US5869281A (en) * 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
WO1995000552A1 (en) 1993-06-25 1995-01-05 Merck Frosst Canada Inc. Prostaglandin receptor ep3 and dna encoding it
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) * 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
WO1995011033A1 (en) 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
US5431881A (en) * 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
DK0736018T3 (da) * 1993-12-20 2000-09-18 Fujisawa Pharmaceutical Co 4,5-Diaryloxazolderivater
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
ZA95627B (en) 1994-01-28 1995-10-05 Procter & Gamble Biodegradable copolymers and plastic articles comprising biodegradable copolymers
US5476372A (en) 1994-02-10 1995-12-19 Yang; Hsi-Kung Manual pump
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
CN1092639C (zh) * 1995-01-06 2002-10-16 东丽株式会社 苯稠合杂环衍生物及其用途
JP3064015B2 (ja) * 1995-01-26 2000-07-12 メルク フロスト カナダ アンド カンパニー プロスタグランジンレセプターｄｐ
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
FR2730811B1 (fr) 1995-02-17 1997-03-21 Oreal Procede pour diagnostiquer et/ou suivre l'evolution d'un desordre capillaire et/ou mesurer l'efficacite d'un traitement applique pour combattre un desordre capillaire
DE69613693T2 (de) 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5990346A (en) * 1995-06-26 1999-11-23 Teijin Limited Prostaglandins and processes for production thereof
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
AU7271996A (en) 1995-10-23 1997-05-15 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
AU7680096A (en) 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5994397A (en) * 1995-12-22 1999-11-30 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
WO1997023226A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
JP3049593B2 (ja) * 1996-05-01 2000-06-05 株式会社ビメーク 育毛・養毛剤
AU3588797A (en) 1996-07-03 1998-01-21 Board Of Regents Of The University Of Oklahoma, The Enhancement of skin pigmentation by prostaglandins
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
EP0930296B2 (de) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorierte prostaglandinderivate und medikamente
US5827508A (en) 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
JP3537274B2 (ja) 1996-10-29 2004-06-14 鐘淵化学工業株式会社 生分解性を有する積層体
CA2270349A1 (en) 1996-11-01 1998-05-14 Jesse A. May Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
CA2269855A1 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
CA2269853A1 (en) 1996-11-12 1998-05-22 Paul W. Zinke Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives
WO1998020881A1 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
DK0951282T3 (da) 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
DE69823852T2 (de) * 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ATE237587T1 (de) 1997-02-10 2003-05-15 Ono Pharmaceutical Co 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
CA2253717A1 (en) 1997-02-27 1998-09-03 Toray Industries Inc. Drugs for ameliorating pulmonary circulation
AU6545498A (en) 1997-03-07 1998-09-22 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
JP3217293B2 (ja) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
JP2002501533A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 高眼圧症治療のための眼科用組成物
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
WO1999012553A1 (en) 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
EP1011707B1 (de) 1997-09-08 2007-10-31 The University of Medicine and Dentistry of New Jersey Epitope der gp120 v1/v" domäne von hiv-1 geeignet zur herstellung neutralisierender antikörper
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
EP1012138A1 (de) 1997-09-09 2000-06-28 The Procter & Gamble Company Verfahren zur herstellung von 13,14-dihydro-15-substituierte 16-tetranor pg f,e and a derivate
JP2001515866A (ja) 1997-09-09 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロサポシン受容体アゴニストを利用したアポトーシスの阻害
ID24845A (id) * 1997-09-09 2000-08-24 Procter & Gamble Prostaglandin tetrahidro tersubstitusi c16-c20 aromatik yang berguna sebagai agonis fp
AU9305898A (en) * 1997-09-09 1999-03-29 Procter & Gamble Company, The A process for making prostaglandin f analogs
WO1999012550A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume
CA2303764C (en) * 1997-09-09 2005-02-15 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
KR20010023837A (ko) * 1997-09-09 2001-03-26 데이비드 엠 모이어 Ｆｐ 작동약으로 유용한 방향족 ｃ16-ｃ20-치환된테트라히드로 프로스타글란딘
BR9812068A (pt) 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
HUP0004581A2 (hu) 1997-09-09 2001-05-28 The Procter & Gamble Co. Eljárás csonttérfogat növelésére nem természetes előfordulású FP szelektív agonisták alkalmazásával
WO1999012560A1 (en) 1997-09-09 1999-03-18 Creative Biomolecules, Inc. Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors
AU9312598A (en) 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
AU731842B2 (en) 1997-09-10 2001-04-05 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
JP2001515706A (ja) 1997-09-11 2001-09-25 パーデュー・リサーチ・ファウンデーション ガラクトシダーゼ変性粘膜下組織
DE69828414T2 (de) 1997-09-11 2005-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mukosale zytotoxische t-lymphozytenantwort
EP1024821A1 (de) 1997-09-12 2000-08-09 Smithkline Beecham Corporation Neue prokaryotische polynukleotide und polypeptide und deren verwendung
CA2271475A1 (en) 1997-09-17 1999-03-25 Masami Moriyama Cervical ripening agent
ATE253047T1 (de) 1997-09-19 2003-11-15 Shionogi & Co Verbindungen mit (2.2.1)bicyclischer molekülstruktur
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
ES2214753T3 (es) 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
CN1282249A (zh) 1997-12-18 2001-01-31 内森·厄尔·斯科特 用于治疗阳痿和增强性唤起的前列腺素E2/F2α组合剂
US6099870A (en) 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AU1334899A (en) 1997-12-22 1999-07-12 De Groot, Marcellus Johannes A. A process for site-directed integration of multiple copies of a gene in a mould
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
WO1999047497A2 (en) 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
PL343125A1 (en) 1998-03-31 2001-07-30 Procter & Gamble C11
EP1082299B1 (de) 1998-03-31 2004-06-30 Duke University C11-oxymyl- and hydroxylamino-prostaglandine und ihre anwendung als arzneimittel
CA2333038C (en) 1998-05-25 2008-12-02 Taisho Pharmaceutical Co., Ltd. Sleep-inducing preparation
US6458549B2 (en) 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2295512C (en) 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
AU5114499A (en) 1998-07-21 2000-02-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2000004898A1 (en) 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AU5196699A (en) 1998-08-12 2000-03-06 Kazusa Dna Research Institute Foundation Novel gene and protein pgth encoded thereby
EP1114816A4 (de) 1998-09-14 2002-09-04 Ono Pharmaceutical Co $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6121253A (en) 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
NZ513826A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
DE60003435T2 (de) 1999-08-04 2004-05-19 The Procter & Gamble Company, Cincinnati Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
CA2393471C (en) 1999-12-30 2008-09-02 The Procter & Gamble Company Biodegradable plastic food service items
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2001072268A1 (en) * 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812193B1 (fr) 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
EP1298223A3 (de) 2001-09-28 2003-07-23 Pfizer Products Inc. Methoden die mit der A-C Wiederholungs-Z-Sequenz stromaufwärts des Aldosereduktasegens in Zusammenhang stehen
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7320967B2 (en) * 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
JP4300833B2 (ja) 2003-03-17 2009-07-22 ソニー株式会社 半導体発光素子の製造方法
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) * 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
JP2007512347A (ja) 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
US7288029B1 (en) 2005-01-19 2007-10-30 Gkn Driveline North America, Inc. Propshaft with crash-worthiness
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2007123818A2 (en) 2006-04-18 2007-11-01 Nitromed, Inc. Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
WO2007125818A1 (ja) 2006-04-24 2007-11-08 Jsr Corporation 重合体及びそれを含有する感光性樹脂組成物
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
JP5095269B2 (ja) 2007-06-05 2012-12-12 北海道エア・ウォーター株式会社 通信システム
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
WO2010096123A2 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010108012A1 (en) 2009-03-18 2010-09-23 Duke University Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins
JP5331025B2 (ja) 2010-02-18 2013-10-30 八千代工業株式会社 サンルーフ装置のガイドパイプの保持構造

Also Published As

Publication number Publication date
US8618086B2 (en) 2013-12-31
US20070092466A1 (en) 2007-04-26
US7407987B2 (en) 2008-08-05
DE60115869D1 (de) 2006-01-19
CN1206976C (zh) 2005-06-22
US20020037914A1 (en) 2002-03-28
EP1267803A2 (de) 2003-01-02
EP1267803B1 (de) 2005-12-14
AU2001251166A1 (en) 2001-10-15
JP2012046545A (ja) 2012-03-08
CA2401718C (en) 2007-05-29
CA2401718A1 (en) 2001-10-11
ES2254395T3 (es) 2006-06-16
WO2001074313A2 (en) 2001-10-11
DE60115869T2 (de) 2006-07-06
JP5579158B2 (ja) 2014-08-27
WO2001074313A3 (en) 2002-02-21
US20080241078A1 (en) 2008-10-02
CN1419437A (zh) 2003-05-21
JP2003528897A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
DE60115869D1 (de) Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen
DE60115000D1 (de) Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.
WO2001074307A3 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
NO20016055L (no) Splitteanordning for murblokker med fremspring i n¶rheten av splitteblader
ATE371475T1 (de) Methoden zur behandlung der hautpigmentierung
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE60308212D1 (de) Verwendung von celluloseperlen zur mattierung der haut
ATE438337T1 (de) Verfahren zum auswerten neuer gehirnschlagsbehandlungen unter verwendung einer geweberisikokarte
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
ATE336242T1 (de) Verwendung von gaboxadol zur behandlung von premenstruelle störung, postnatal depression oder postmenopausal-bedingte-dysphorische störung
DE60319398D1 (de) Verfahren zur herstellung einer pureezusammensetzung enthaltend eine stabilisierte fruchtmarkzusammensetzung
BR0008239A (pt) Processo de redução de crescimento de cabelos em mamìferos, uso de um inibidor de proteìna-tirosina quinase, processo de produção de uma composição para inibir o crescimento de cabelo de mamìferos, e, composição usada para inibir crescimento de cabelo em mamìferos
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
PT1075284E (pt) Uso de um corante vital para facilitar as intervencoes cirurgicas em cirurgia vitreo-retiniana
ATE473729T1 (de) Verfahren zur behandlung von rosacea und telangiectasia
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE50010007D1 (de) Verfahren zur herstellung von wasserstoffperoxid
DE60318342D1 (de) Verwendung eines Granatapfelbaumextrakts zur Erhaltung der Haarfarbe
DE60002529D1 (de) Verfahren zur herstellung von wasserstoffperoxid
ATE451091T1 (de) Kosmetisches peeling-verfahren unter verwendung von harnstoff
ATE370103T1 (de) Verfahren zur behandlung von schlamm
ATE270542T1 (de) Zusammensetzung zur verhinderung der keimbindung
ATE260029T1 (de) Verwendung von anionischen tensiden in heissschäumen zur entfernung von unerwünschten pflanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties